In the context of acute coronary syndrome (ACS), the administration of low-dose interleukin-2 (IL-2) serves primarily as an immunomodulatory intervention designed to mitigate vascular inflammation through the expansion of regulatory T cells (Tregs). Here, IL2 is linked to acute coronary syndrome.